Valeant subpoenaed over pricing; Fidelity manager preaches patience in biotech slump;

@FierceBiotech: Zafgen finally breaks its silence, says it's probing death of a patient. Report | Follow @FierceBiotech

@JohnCFierce: Still trending -- Moderna's top scientist steps down amid a billion-dollar R&D push by @DamianFierce. Article | Follow @JohnCFierce

@DamianFierce: There is perhaps no greater tribute to Steve Jobs than obfuscating your business model and threatening your critics. WSJ story | Follow @DamianFierce

> Federal prosecutors have subpoenaed Valeant Pharmaceuticals ($VRX) for more information on how it prices drugs. Story

> Biotech's recent troubles on Wall Street are part of a "manic-depressive" period that will pass, Fidelity fund manager Rajiv Kaul told Bloomberg. More

> Transition Therapeutics ($TTHI) said its Alzheimer's disease treatment charted a clinical benefit on a Phase II trial among patients with agitation and aggression related to the disease, despite missing its primary endpoint. News

Medical Device News

@FierceMedDev: Intelesens gets FDA approval for its Zensor wearable vital signs device. More | Follow @FierceMedDev

@VarunSaxena2: California cutbacks: BD cuts 95 at CareFusion; Medtronic to cut 21 at distribution facility. Report | Follow @VarunSaxena2

@EmilyWFierce: Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. FiercePharma report | Follow @EmilyWFierce

> Astute Medical to launch its diagnostic in China thanks to $20M investment from FosunPharma. Report

> 23andMe adds chapter to comeback story with $115M in funding. Article

Pharma News

@FiercePharma: ICYMI: Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Mylan hopes new show-and-tell will woo Perrigo shareholders. Story | Follow @CarlyHFierce

> Valeant hit with two federal subpoenas as drug-price controversy rages on. Story

> Pfizer CEO: Drug-pricing snafu isn't pharma's fault. It's insurers and their poor coverage. More

> Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. Article

CRO News

> INC bolsters its Phase I platform with new cardiac tech. Story

> Aesica bids to manage its clients' many contractors. More

> Cel-Sci lines up cash to fund its $50M suit against ex-partner inVentiv. Report

> CRO Frontage gets into agrochemicals with new service offering. Story

> PRA adds a biotech vet to its board amid an expansion effort. Article

Pharma Manufacturing News

> Myanmar offers incentives to lure its drug distributors into production. News

> Medline recalls 500 mg acetaminophen labeled as 325 mg. More

> Valeant's Bausch + Lomb plant getting $150M in investments, up to 200 jobs. Report

> Chinese company intends to build plant to produce Ebola vax. Article

> GSK selling its drug distribution biz in Romania. Story

Pharma Asia News

> China's State Council urges Suzhou Industrial Park to be more innovative. Story

> Japanese drug regulator opening Indian office. Item

> Lupin inks deal with Boehringer for diabetes drugs in India. News

> Superbug infections drop in China with new controls on antibiotics. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.